n-Butyl orsellinateCAS# 31489-30-2 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
| Cas No. | 31489-30-2 | SDF | Download SDF |
| PubChem ID | N/A | Appearance | Powder |
| Formula | C12H16O4 | M.Wt | 224.3 |
| Type of Compound | Phenols | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
n-Butyl orsellinate Dilution Calculator
n-Butyl orsellinate Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 4.4583 mL | 22.2916 mL | 44.5831 mL | 89.1663 mL | 111.4579 mL |
| 5 mM | 0.8917 mL | 4.4583 mL | 8.9166 mL | 17.8333 mL | 22.2916 mL |
| 10 mM | 0.4458 mL | 2.2292 mL | 4.4583 mL | 8.9166 mL | 11.1458 mL |
| 50 mM | 0.0892 mL | 0.4458 mL | 0.8917 mL | 1.7833 mL | 2.2292 mL |
| 100 mM | 0.0446 mL | 0.2229 mL | 0.4458 mL | 0.8917 mL | 1.1146 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Dehydro-γ-tocopherol
Catalog No.:BCN0430
CAS No.:96273-97-1
- Tetraketide
Catalog No.:BCN0429
CAS No.:276869-83-1
- Tatsiensine
Catalog No.:BCN0428
CAS No.:86695-18-3
- Hyperwightin C
Catalog No.:BCN0427
CAS No.:2374723-87-0
- Hyperwightin D
Catalog No.:BCN0426
CAS No.:2374723-88-1
- Hyperwightin E
Catalog No.:BCN0425
CAS No.:2374723-89-2
- Hyperwightin B
Catalog No.:BCN0424
CAS No.:2374723-86-9
- Deacetyltatsiensine
Catalog No.:BCN0423
CAS No.:86695-19-4
- Acrofolione A
Catalog No.:BCN0422
CAS No.:820975-61-9
- 8-Oxoeremophil-6-en-12-oic aicd
Catalog No.:BCN0421
CAS No.:1313436-97-3
- Acetyldihydromicromelin B
Catalog No.:BCN0420
CAS No.:1427351-73-2
- (3R)-Hydroxyibogaine
Catalog No.:BCN0419
CAS No.:2276636-13-4
- Euscapholide
Catalog No.:BCN0432
CAS No.:220862-15-7
- Acrofolione B
Catalog No.:BCN0433
CAS No.:820975-62-0
- Gnetifolin A
Catalog No.:BCN0434
CAS No.:137476-72-3
- Siwanine B
Catalog No.:BCN0435
CAS No.:159903-63-6
- Tuberostemonine D
Catalog No.:BCN0436
CAS No.:1627827-84-2
- 19-Hydroxypseudovincadifformine
Catalog No.:BCN0437
CAS No.:2340171-73-3
- Genipin 10-O-glucoside
Catalog No.:BCN0438
CAS No.:1947317-95-4
- Cyclobutanedichalcone
Catalog No.:BCN0439
CAS No.:861706-38-9
- Farfugin A
Catalog No.:BCN0440
CAS No.:36061-18-4
- Acrovestenol
Catalog No.:BCN0441
CAS No.:864679-69-6
- Borneol glucuronide
Catalog No.:BCN0442
CAS No.:1642562-41-1
- 19-Epivoacristine
Catalog No.:BCN0443
CAS No.:6883-77-8
In vitro antitumour activity of orsellinates.[Pubmed:20355320]
Z Naturforsch C J Biosci. 2010 Jan-Feb;65(1-2):43-8.
Lichen phenolic compounds exhibit antioxidant, antimicrobial, antiproliferative, and cytotoxic activities. The purpose of this study was to evaluate the anticancer activity of lecanoric acid, a secondary metabolite of the lichen Parmotrema tinctorum, and its derivatives, orsellinates, obtained by structural modification. A cytotoxicity assay was carried out in vitro with sulforhodamine B (SRB) using HEp-2 larynx carcinoma, MCF7 breast carcinoma, 786-0 kidney carcinoma, and B16-F10 murine melanoma cell lines, in addition to a normal (Vero) cell line in order to calculate the selectivity index of the compounds. n-Butyl orsellinate was the most active compound, with IC50 values (the concentration that inhibits 50% of growth) ranging from 7.2 to 14.0 microg/mL, against all the cell lines tested. The compound was more active (IC50 = 11.4 microg/mL) against B16-F10 cells than was cisplatin (12.5 microg/mL). Conversely, lecanoric acid and methyl orsellinate were less active against all cell lines, having an IC50 value higher than 50 microg/mL. Ethyl orsellinate was more active against HEp-2 than against MCF7, 786-0, or B16-F10 cells. The same pattern was observed for n-propyl and n-Butyl orsellinates. n-Pentyl orsellinate was less active than n-propyl or n-Butyl orsellinates against HEp-2 cells. The orsellinate activity increased with chain elongation (from methyl to n-butyl), a likely consequence of an increase in lipophilicity. The results revealed that the structural modification of lecanoric acid increases the cytotoxic activity of the derivatives tested.
